As of 2026-03-14, the EV/EBITDA ratio of Cara Therapeutics Inc (CARA) is 0.22. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CARA's latest enterprise value is -13.59 mil USD. CARA's TTM EBITDA according to its financial statements is -61.10 mil USD. Dividing these 2 quantities gives us the above CARA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.0x - 11.1x | 8.7x |
| Forward P/E multiples | 12.5x - 14.1x | 12.9x |
| Fair Price | (158.56) - (140.64) | (136.10) |
| Upside | -3080.4% - -2743.7% | -2658.2% |
| Date | EV/EBITDA |